Tennis Star Monica Seles Partners with Shire to Raise Awareness of Binge Eating Disorder in Adults
BEDA and NEDA Support National Public Service Announcement (PSA) and Campaign to Bring Attention to the Most Common Eating Disorder in US Adults
B.E.D. is a distinct medical condition recognized by the American Psychiatric Association. It is a more common eating disorder than anorexia and bulimia combined, affecting an estimated 2.8 million US adults, according to a national survey.* B.E.D. is characterized by regularly eating far more food than most people would eat in a similar time period, with binges taking place on at least a weekly basis for three months. Adults with B.E.D. feel that their eating is out of control during a binge and find binges very upsetting, among other symptoms. B.E.D. is more than overeating and, unlike other eating disorders, people with B.E.D. don’t routinely try to “undo” their excessive eating with extreme actions like purging or over-exercising. B.E.D. occurs in both men and women.
“There is a misconception that adults with B.E.D. fit a certain profile” said Monica Seles. “I felt ashamed about my binge eating for so long, and my hope is that hearing the stories of people like me, and having information about the disorder more publicly available, may help inspire other adults to get the support they need.” Seles also wrote about her experience in her book, Getting a Grip: On My Body, My Mind, My Self.
The national campaign is also supported by the efforts of Sunny Sea Gold, author of Food: the Good Girl’s Drug. “It wasn’t until I started getting help that I really understood that B.E.D. is not a personality issue, but a real, medical disorder affecting many adults,” said Sunny Sea Gold. “This empowered me to start having productive conversations with my family and my health care providers.”
The campaign website, BingeEatingDisorder.com, features information about B.E.D. and how to recognize the symptoms, its potential causes, experiences of others with B.E.D., including a series of public service announcements (PSAs), and tips for how to raise the topic with health care providers and loved ones. “We are proud to be joined by such a great team of partners to provide education for adults who may have B.E.D.,” said Perry Sternberg, Head of Shire’s Neuroscience Business Unit. “Shire’s focus on awareness of B.E.D. in adults is part of our ongoing commitment to meeting unmet needs of adults with this condition.”
“We are aware that many adults may experience symptoms for a long time before speaking to a health care provider, and we hope that this will help encourage them to get the support they need,” said Chevese Turner, Founder, President and Chief Executive Officer, BEDA. “We are thrilled to be able to continue our work supporting adults with B.E.D. with the launch of this campaign.”
While B.E.D. often starts in early adulthood, only 3 percent of US adults in an online survey who met B.E.D. criteria in the past 12 months reported having been diagnosed with the condition by a health care provider.** Additionally, fewer than 50 percent of adults with B.E.D. are obese, based on a national survey of U.S. adults.***
“We are pleased to be participating in this campaign as it fits within NEDA’s overall commitment to raising awareness of eating disorders,” said Lynn Grefe, CEO and President. “Given the prevalence and lack of awareness of B.E.D., we feel it essential to bring particular attention to B.E.D. as the most common eating disorder among US adults.”
*Based on 12-month prevalence estimates applied to the full US population aged ≥18 years.
**Data from a 2013 online survey of adults aged ≥ 18 years. Of 22,397 respondents, 344 met diagnostic criteria for B.E.D. in the previous month.
***Data from a sample of 2,980 adults aged ≥ 18 years who were assessed for an eating disorder in a national survey.
B.E.D. is a distinct eating disorder now recognized in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition(DSM-5®). B.E.D. is characterized by regularly eating far more food than most people would eat in a similar time period under similar circumstances, with binges taking place on at least a weekly basis for three months. Adults with B.E.D. feel that their eating is out of control during a binge and find binges very upsetting.
As described in the DSM-5®, binge eating episodes are associated with three (or more) of the following: eating extremely fast, eating beyond feeling full, eating large amounts of food when not hungry, eating alone to hide how much one is eating, and feeling bad about oneself after a binge. Unlike people with other eating disorders, people with B.E.D. don’t routinely try to “undo” their excessive eating with extreme actions like purging and over-exercising. Binge Eating Disorder is not part of another eating disorder. All of the criteria defined in DSM-5® must be met in order to make a diagnosis of B.E.D. by a health care provider.
Founded in 2008, the Binge Eating Disorder Association (BEDA) is a national organization focused on providing leadership, recognition, prevention, and management of B.E.D. Through outreach, education and advocacy, BEDA will facilitate increased awareness and proper diagnosis of B.E.D., and promote excellence in care for those who live with B.E.D. and its associated conditions. BEDA is committed to promoting cultural acceptance of, and respect for, the natural diversity of sizes, as well as promoting a goal of improved health.
The National Eating Disorders Association (NEDA) is the leading non-profit organization in the United States advocating on behalf of and supporting individuals and families affected by eating disorders. Reaching millions every year, NEDA campaigns for prevention, education, access to care and increased research funding to better understand and treat eating disorders. NEDA works with partners and volunteers to develop programs and tools to help everyone who seeks assistance. nationaleatingdisorders.org
For further information please contact:
Sarah Elton-Farr firstname.lastname@example.org +44 1256 894157
Stephanie Fagan email@example.com +1 201 572 9581
Gwen Fisher firstname.lastname@example.org +1 484 595 9836
Jessica Cotrone email@example.com +1 781 482 9538
NOTES TO EDITORS
Shire enables people with life–altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
THE “SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included in this communication that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that:
- Shire’s products may not be a commercial success;
- revenues from ADDERALL XR and INTUNIV are subject to generic erosion;
- the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payors in a timely manner for Shire's products may impact future revenues, financial condition and results of operations;
- Shire conducts its own manufacturing operations for certain of its products and is reliant on third party contract manufacturers to manufacture other products and to provide goods and services. Some of Shire’s products or ingredients are only available from a single approved source for manufacture. Any disruption to the supply chain for any of Shire’s products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time.
- the development, approval and manufacturing of Shire’s products is subject to extensive oversight by various regulatory agencies. Submission of an application for regulatory approval of any of our product candidates, such as our planned submission of a New Drug Application to the FDA for lifitegrast, may be delayed for any number of reasons and, once submitted, may be subjected to lengthy review and ultimately rejected. Moreover, regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;
- the actions of certain customers could affect Shire's ability to sell or market products profitably. Fluctuations in buying or distribution patterns by such customers can adversely impact Shire’s revenues, financial conditions or results of operations;
- investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire’s activities in the highly regulated markets in which it operates may result in significant legal costs and the payment of substantial compensation or fines;
- adverse outcomes in legal matters and other disputes, including Shire’s ability to enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on Shire’s revenues, financial condition or results of operations;
- Shire faces intense competition for highly qualified personnel from other companies, academic institutions, government entities and other organizations. Shire is undergoing a corporate reorganization and the consequent uncertainty could adversely impact Shire’s ability to attract and/or retain the highly skilled personnel needed for Shire to meet its strategic objectives;
- failure to achieve Shire’s strategic objectives with respect to the acquisition of ViroPharma Incorporated may adversely affect Shire’s financial condition and results of operations;
- Shire’s proposed acquisition of NPS Pharma may not be consummated due to the occurrence of an event, change or other circumstances that gives rise to the termination of the merger agreement;
- a governmental or regulatory approval required for the proposed acquisition of NPS Pharma may not obtained, or may be obtained subject to conditions that are not anticipated, or another condition to the closing of the proposed acquisition may not be satisfied;
- NPS Pharma may be unable to retain and hire key personnel and/or maintain its relationships with customers, suppliers and other business partners pending the consummation of the proposed acquisition by Shire, or NPS Pharma’s business may be disrupted by the proposed acquisition, including increased costs and diversion of management time and resources;
- difficulties in integrating NPS Pharma into Shire may lead to the combined company not being able to realize the expected operating efficiencies, cost savings, revenue enhancements, synergies or other benefits at the time anticipated or at all;